非妇科细胞病理诊断报告是否应纳入恶性风险的不确定性
该文讨论非妇科诊断性细胞病理报告中是否应纳入恶性风险(ROM)的不确定性,并汇总多个解剖部位确诊恶性时的已知假阳性率。作者认为,将特定标本的已知假阳性率写入报告有助于说明诊断局限并促进临床决策。
要点
- 确诊恶性时各部位细胞学假阳性率低但存在,报告可注明以说明局限
- ROM数据受部位、标本类型、染色、分子检测及机构与时间差异影响
- 将已知假阳性率纳入报告有助于临床管理和医患共同决策
核心结论
- 作者认为可将特定诊断性细胞标本的已知假阳性率写入细胞学报告,以说明诊断局限并辅助临床决策。
研究设计与样本
- 本文为针对选定常规诊断性细胞标本的简要文献综述,汇总已发表的恶性风险(ROM)数据。
主要发现
- 确诊恶性时,胆管刷检ROM约99%(范围97%-100%),乳腺细针穿刺98.5%(范围92%-100%)。
- 浆液性积液ROM为98.9%(范围90%-100%),但鳞状细胞癌、间皮瘤和淋巴瘤较低。
- 肺动脉超声内镜细胞学ROM约99%(范围86.6%-100%),甲状腺细针穿刺98%(排除NIFTP时范围97%-99%)。
- 涎腺细针穿刺ROM约90%(范围57%-100%),侧颈部囊肿细针穿刺约99%(范围95.5%-100%)。
临床怎么用
- 在诊断性细胞病理报告中可注明该标本类型的已知假阳性率,以解释诊断局限并支持临床决策。
局限性
- ROM数据受解剖部位、标本性质、染色方法、分子检测及机构与判读者差异影响,且随时间变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In diagnostic cytology, the known site-specific false positive rates at various anatomical sites for the risk malignancy (ROM) when a confirmed malignant diagnosis is made are comparatively well documented. ROM figures for diagnostic cytology specimens may vary according to the anatomical site of the specimen, the exact nature of the specimen received, the staining method(s) used, and the use of additional laboratory techniques including molecular profiling; furthermore, they often differ to some extent from institution to institution, between differing cytologists within the same institution, and over time. A brief literature review for a selected group of routine diagnostic cytology specimens shows a published ROM for a confirmed malignant diagnosis as follows: bile duct brushings, ~99% (range, 97%-100%); breast fine needle aspiration, 98.5% (range, 92%-100%); serous effusion fluid, 98.9% (range, 90%-100% although lower for squamous cell carcinoma, mesothelioma, and lymphoma), pulmonary endobronchial ultrasound cytology, ~99% (range, 86.6%-100%); thyroid FNA, 98% (range, 97%-99% if NIFTP tumors are excluded), salivary gland FNA, ~90%; (range 57%-100%) and lateral neck cyst FNA, ~99% (range, 95.5%-100%). Because most diagnostic cytology specimens have a small but accepted false-positive rate, this information is vitally important for the clinical management of patients and for shared patient decision making. In our view, the known false-positive rate for a given diagnostic cytology specimen could be included within the cytology report to assist in explaining the limitations of the diagnostic cytology interpretation and help facilitate the clinical decision-making process.
引用
- Poller DN, Schmitt F. Should uncertainty concerning the risk of malignancy be included in diagnostic (nongynecologic) cytopathology reports? Cancer Cytopathol. 2020. PMID: 32649050. doi:10.1002/cncy.22322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。